Developing advanced fluorescent nanoparticles for improved cell analysis
An expanded 75-color panel of Pdots for spectral multiplexing
This study is working on a new type of tiny particles that can help doctors see and understand different types of cells in your body better, which could lead to more accurate tests and treatments for autoimmune diseases and cancers.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lamprogen, INC. NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10897281 on NIH RePORTER |
What this research studies
This research focuses on enhancing flow cytometry techniques by creating a new family of ultrabright fluorescent nanoparticles, known as Pdots. These nanoparticles will allow for better detection and analysis of various cell types, including B cells and T cells, by providing clearer spectral signatures. The approach aims to simplify the process of identifying overlapping signals from different fluorescent markers, which can improve the resolution of cell subpopulations in clinical diagnostics and research. Patients may benefit from more accurate diagnostic tools and treatments for autoimmune diseases and cancers as a result of this work.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with autoimmune diseases or cancers who may benefit from improved diagnostic techniques.
Not a fit: Patients who do not have autoimmune diseases or cancers may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more precise diagnostic tools and therapies for patients with autoimmune diseases and cancers.
How similar studies have performed: Other research has shown success with similar approaches in enhancing flow cytometry techniques, making this a promising area of investigation.
Where this research is happening
Seattle, United States
- Lamprogen, INC. — Seattle, United States (Active)
Researchers
- Principal investigator: Yu, Jiangbo — Lamprogen, INC.
- Study coordinator: Yu, Jiangbo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.